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Summary The numbers of potentially tumorigenic cancer cells released into the circulation and secondarily
arrested in the lungs of mice bearing B16F1O melanomas or Lewis lung carcinomas were systematically
quantified throughout i.m. tumour growth using a bioassay procedure capable of detecting as few as 10 to
100 tumorigenic cells in the circulation or lungs. Viable disseminating cancer cells were detectable within 4
days of i.m. tumour growth and reached 106 per 0.5 ml of blood in carcinoma-bearers and 2 x 104 per 0.5 ml
in melanoma-bearers; 98% of mice with circulating cancer cells had potentially tumorigenic cells in their
lungs, even in the absence of overt metastases. The numbers of cancer cells present in the circulation and
lungs were related to the growth rate of the i.m. lesion, more cells being released from faster-growing
tumours. The numbers of tumorigenic carcinoma cells were compared with the total numbers of cells released
into the circulation as quantitated by direct counting procedures, and it was found that the vast majority of
these circulating cells were potentially tumorigenic. These studies provide quantitative information about
cancer cell input into the metastatic process. Also, the bioassay procedure provides a useful experimental
model for the development of regimens for therapy of metastases since it is a sensitive method of monitoring
not only the size of disseminated populations of cancer cells but also their clinically relevant property namely,
their tumorigenic potential.
In order to understand the multi-step processes
involved in the production of overt metastases, it is
essential to develop methods to quantify cancer cell
input into the various steps. Such data can be used
to identify potentially rate-limiting stages and, when
integrated, will give a more comprehensive picture
of the metastatic process as a whole. The work
presented here focusses on the numbers of cancer
cells released from primary tumours into the
circulation and subsequently arrested in the lungs.
Evaluation of the biologic significance of circulating
cancer cells is hindered by the relatively few
attempts to systematically quantitate cancer cells in
the blood in relation to tumour growth and
metastasis (Liotta et al., 1974; Butler & Gullino,
1975; Schirrmacher & Waller, 1982). Attempts to
quantitatively determine the malignant potential of
circulating cancer cells have been even fewer
(Dobrossy & Turi, 1976; Nakadate et al., 1979) but
in the present study, a sensitive bioassay has been
developed to determine both the numbers and
potential tumorigenicity of circulating cancer cells.
The bioassay has also been applied to the
quantitation of cancer cells disseminated to the
lungs. Such assays are much needed to detect
disseminated tumour cells before they become overt
lesions, especially with regard to monitoring the
potential effectiveness of various forms of cancer
therapy.
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The Lewis lung carcinoma (Sugiura & Stock, 1955)
was routinely transplanted in C57BL/6J female
mice aged 8-10 weeks (Jackson Labs., ME). Single-
cell suspensions were prepared by incubation of
minced tumour tissue with a solution containing
0.25% neutral protease (Type IX, Sigma, MO),
0.25% collagenase (Type IV, Sigma, MO), and
0.02% DNAase (Deoxyribonuclease I, Sigma, MO)
in Hanks' balanced salt solution (HBSS) for 15min
at 37°C with stirring. Liberated tumour cells were
washed twice with HBSS and filtered through 400
gauge stainless steel mesh to remove any cell
clumps. The B16FIO variant of the B16 melanoma
(Fidler, 1973) was maintained in tissue culture as
previously described (Weiss et al., 1982) and
cultured melanoma cells were used to induce the
intramuscular tumours from which cells for
experiments were prepared by the same procedures
used in isolation of Lewis lung carcinoma cells.
Lewis and B16F1O tumour cell viability after
isolation was routinely >90% as assessed by
trypan blue exclusion.
Intramuscular andpulmonary tumour growth
Intramuscular tumours were initiated by
inoculation into a hind limb of C57B13/6J mice, age
6-8 weeks, with 105 viable cells derived from solid
tumours and tumour size was determined from the
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average of caliper measurements made in two axes
minus the average diameter of the contralateral,
tumour-free leg. Tumour volumes were calculated
from this data as previously described (Weiss et al.,
1982). The incidence of pulmonary metastases from
B16F10 melanomas was assessed while lungs were
processed for bioassay. The incidence of Lewis lung
carcinoma metastases was not recorded in bioassay
experiments since, unlike pigmented melanoma
nodules, nodules of 1 mm or less are not reliably
identifiable without the use of a dissecting
microscope. Such manipulations necessitate delays
in processing and increased chances for microbial
contamination which could alter the tumorigenicity
of any cancer cells present in the sample.
Quantitation oftumorigenic cells in lungs and
peripheral blood
Bioassays were developed to quantitate the
numbers of tumorigenic cancer cells in both lungs
and peripheral blood of tumor-bearing mice.
Basically, the bioassay determines the number of
tumorigenic cells in an i.p. inoculum containing an
initially unknown number of cells from the time
taken for recipient mice to die after inoculation.
The bioassay is based on the assumptions that mice
die with approximately constant tumour loads and
that cell growth kinetics are approximately
independent of numbers of cells inoculated. These
bioassays are essentially extensions of similar
quantitative bioassays used in evaluations of
therapeutic agents on leukaemias (Skipper et al.,
1964, 1965). In a control series of experiments used
to validate bioassay procedures, known numbers of
melanoma or Lewis carcinoma cells were mixed
with either (a) 106 melanoma or carcinoma cells
attenuated by exposure to 50Gy gamma radiation
or (b) minced normal mouse lung tissue or (c)
0.5ml heparin-anticoagulated normal mouse blood
and 106 irradiated cancer cells. These mixtures were
injected into the peritoneal cavities of C57BL/6J
mice and survival times measured.
In experiments with tumour-bearing mice,
animals were given 105 tumour cells i.m. on Day 0
and at subsequent intervals, groups of mice were
anesthetized with chloroform and 0.5ml of blood
removed by cardiac puncture of the right ventricle.
The blood was anticoagulated with 1 unitml- 1
heparin, mixed with 106 lethally-irradiated "carrier"
melanoma or Lewis carcinoma cells and injected
i.p. into normal mice. The lungs from the same
tumour-bearers were excised, minced, and injected
i.p. into a second group of normal animals. The
survival times of these bioassay mice were then
determined. The mean survival times of control
mice given known numbers of viable tumour cells,
isolated from the same tumour used to induce i.m.
tumours in each experimental series and mixed with
106 irradiated carrier cells of the appropriate
tumour cell type were also determined and plotted
graphically. The numbers of tumorigenic cells in the
blood or lungs of tumour-bearing mice were then
found by comparing the survival times of bioassay
recipients with survival times of the control mice
injected with known numbers of viable tumour cells
as described above.
Lung colonization potential ofmelanoma and
carcinoma cells
Graded doses of melanoma or Lewis carcinoma
cells were injected via a caudal vein and the
numbers of pulmonary nodules determined 21 days
later following post-mortem fixation of the lungs




The results of control experiments to validate
bioassay procedures for viable melanoma and
carcinoma cells are given in Tables I and II. Direct
comparisons were made between the survival times
of mice after injection of the two types of tumour
cells mixed with other cells or tissues. For each
dose/cell mixture, two or three experiments were
made and survival data from these experiments
were similar. For example, the survival times of
groups of 10 mice injected i.p. with 105 B16FIO
cells only were 23.6±3.8, 23.8+5.6 and 22.7+2.9
days. Survival times of groups of 10 mice injected
with 105 B16FIO cells plus carrier cells in three
experiments were 19.9±1.7, 20.0+3.1 and
21.0+2.1 days. The mean survival data of all
experiments best fit lines of the form l/Td=I+m
log c where l/Td is the average inverse time of
death in days following an injection of c cells. For
B16F10 cells the lines for cells only, cells plus
carrier and cells plus lung mince had the same
(P<0.05) slope (m) 9.27 x 10-3+0.89 x 10-3 and
probably the same intercept I, zero. The repression
coefficients for the 3 lines were 0.96, 0.99, and 0.99
respectively. The slope, intercept, and regression
coefficient for cells plus blood plus carrier were
6.14 x10-3+0.51 X 10-3, 16.6 x 10-3+ 1.98 x 10-3
and 0.99 respectively. There were no significant
differences between lines calculated as above for the
Lewis lung carcinoma groups shown in Table II.
The pooled slopes, intercepts and regression
coefficients were 1.06 x 10-2+0.07x 10-2,
2.12x 10-2+0.27 x 10-2 and 0.99 respectively.
The use of survival times to estimate the number
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Table I Bioassay of B16F10 melanoma cells
Mean survival time [days+±s.d. (no. mice)]
No. cells B16FJO B16FJO+ B16FJO+ BJOFJO+blood
injected i.p. only carrier cellsa lung minceb +carrier cells
106 17.3+2.5 (10/10) 15.9+ 1.6 (10/10) 16.1+2.2 (10/10) 19.0+ 2.9 (10/10)
105 22.7+2.9 (10/10) 19.9+ 1.7 (10/10) 19.8+1.1 (10/10) 20.2+ 3.1 (10/10)
104 28.3+1.2(10/10) 25.1+ 4.4(10/10) 26.1+1.2(10/10) 25.3+ 3.7 (10/10)
103 39.3+ 1.7 (4/10) 34.6+ 8.2 (10/10) 35.4+1.2 (10/10) 34.7+11.5 (10/10)
102 39 (1/9) 49.1 + 7.9 (9/10) 47.6+2.3 (10/10) 39.0+ 7.8 (8/10)
101 - (0/10) 63.8 +10.4 (5/10) Not done 59.7+12.3 (3/10)
a106 Bl6F10 cells exposed to 50Gy gamma radiation.
bB16F1O cells were added to normal lungs and the mixture minced before injection.
C0.5ml heparinized normal mouse blood.
Table II Bioassay of Lewis lung carcinoma cells
Mean survival time [days+s.d. (no ofmice)]
Lewis carcinoma+
No. cells Lewis carcinoma Lewis carcinoma blood+carrier
injected i.p. +carrier cells +lung mince cells
106 12.9+3.0 (10/10) 12.0+2.6 (5/5) 11.0+ 0.9 (10/10)
105 14.8+3.2 (10/10) 13.3± 1.9 (5/5) 12.7+ 1.4 (10/10)
104 18.0+3.0 (10/10) 16.0+1.6 (5/5) 15.5+ 0.9 (10/10)
103 20.2+2.8 (10/10) 20.0+1.6 (5/5) 18.0+ 0.9 (10/10)
102 22.5+5.9 (6/10) 26.0+1.8 (4/5) 25.5+ 6.7 (10/10)
101 32 (1/10) Not done 31.4+12.1 (5/10)
type of regression line. Such a procedure does not
permit estimation of a standard error due to the
fact that standard errors are estimated from the
variance in a sample population. The method used
to determine regression curves assumes the number
of cells inoculated to be exact. Therefore, there is
no information available to determine s.e. but it is
possible to calculate 95% confidence levels. In the
units used in these experiments, the 95% confidence
levels are approximately ± 1 log1o unit and the
calculated "range" data shown in Tables III and IV
take these confidence limits into account.
The data in Table I also clearly show that the
addition of carrier cells, lung mince, and blood plus
carrier to B16F10 cells enhanced the number of
tumour takes at low cell inocula compared with the
incidence of takes in mice given B16F1O cells only.
For instance, 102 B16F1O cells grew in only 1/9
mice but the incidence of growth from the same
dose of cells mixed with carrier cells was 90%
(P<0.05, chi2 test), or with lung mince was 100%
(P<0.05, chi2 test) or with blood plus carrier cells
was 80% (P<0.05, chi2 test). Even at inocula of as
few as 10 cells, significant numbers of mice
developed tumours in the presence of "carrier"
cells. Thus, the threshold sensitivity of the
bioassays is in the range of 10-100 tumorigenic cells
and such survival data can be used to determine the
numbers of tumorigenic cancer cells in the lungs
and blood of tumour-bearing mice.
Tumorigenic cells in circulation and lungs ofB16FJO
melanoma-bearing and Lewis lung carcinoma-bearing
mice
The peripheral blood and lungs of groups of mice
bearing i.m. B16F1O melanomas were bioassayed at
intervals throughout i.m. tumour growth in two
separate experiments and the results are given in
Table III. In the second experiment the primary
i.m. tumours did not achieve the same sizes as in
the first experiment, even though the same numbers
of cells (105) were initially inoculated and survival
times were comparable (23.2+2.9 and 25.7+2.5
days respectively). Nevertheless, the results of the
two experiments were essentially similar in that
progressively more animals had tumorigenic cells in
their circulation and/or lungs as the i.m. tumour
reached lethal proportions.
Two series of bioassay experiments were also162 E. MAYHEW & D. GLAVES
Table III Tumorigenic cells in circulation and lungs of BI6F10 melanoma-bearing mice
Tumorigenic cells in lungs Tumorigenic cells in blooda Pul Tumour age Tumour vol. Pulmonary
(days) ( s.d.) Median Range Incidence Median Range Incidence metastasis
Expt. 1
4 < 1.0 * * 0/10 * *- < 100 1/10 0/10
7 < 1.0 * * 0/10 * * 0/10 0/10
11 1.9+0.9 <100 *104 5/10 * *-<100 1/10 0/10
14 Not done <100 *104 7/10 * *<100 2/10 0/10
18 6.0+1.8 500 *-5 x 106 8/10 < 100 *-3 x 103 5/10 3/10
20 8.5+1.3 500 *-5 x 106 9/10 * *104 4/10 3/10
22 10.0+ 1.3 103 < 100-5x 106 15/15 5 x 102 *104 9/15 11/15
Expt. 2
4 <0.1 * * 0/10 * * 0/10 0/10
7 0.1 +0.04 * * 0/10 * * 0/10 0/10
I1 0.5 +0.3 * * 3 x 103 3/10 * * 3x 103 1/10 0/10
14 1.4+0.9 500 *-66x 103 8/10 * *_104 4/10 0/10
18 3.2+0.9 2 x 103 *-8 x 104 9/10 6 x 102 *7 x 104 5/10 0/10
21 5.5+ 1.6 5 x 103 800-8 x 104 10/10 6 x 103 *2 x 104 8/10 0/10
ao.5ml.
*None detectable.
Table IV Tumorogenic cells in circulation and lungs of Lewis lung carcinoma-bearing mice
Tumour age Tumour vol. Tumorigenic cells in lungs Tumorigenic cells in blooda
(days) ( s.d.) Median Range Incidence Median Range Incidence
Expt. 1
4 <0.1 * * 0/10 * * 0/10
7 <0.1 * * 0/10 * * 0/10
11 0.3+0.1 * *103 4/10 * *3 x 103 3/10
14 1.2+0.5 104 400- 105 10/10 103 *5x 104 8/10
18 2.1+0.6 4 x 105 400- 106 9/10 104 400-5 x 104 9/10
21 2.9+0.8 106 104-3 x 106 10/10 5 x 104 7 x103-3 x106 10/10
25 3.8+0.8 3 x 106 *5 x 107 9/10 104 103-5 x 104 9/10
Expt. 2
4 <0.1 * * 0/10 * *- < 100 1/10
7 <0.1 * * 0/10 * *- < 100 1/10
11 <0.1 * * 0/8 * * 0/8
14 0.1 +0.2 < 100 *- 400 5/10 * *- 800 3/10
18 0.7+0.6 103 *-3 x 103 6/9 * *800 3/9
21 1.2+0.8 7 x 103 *-4 x 105 8/9 < 100 *_5 x 104 5/9
25 2.1+ 1.1 7 x 104 *-4 x 105 8/10 < 100 *3 x 103 5/10
28 2.9+ 1.1 5 x 104 *106 7/10 104 *5x 104 7/10
ao.5 ml.
*None detectable.
made with mice bearing i.m. Lewis lung carcinomas
and the results are presented in Table IV. In the
second experiment, the i.m. tumours grew at a
slower rate. Survival times of mice given l0s Lewis
cells i.m. were 24.2+2.2 and 31.8+8.9 days in the
first and second experiments respectively, even
though the survival times of mice injected i.p. with
l0s cells from the same suspension used for i.m.
injections were similar, 15.4+2.1 and 14.8+3.2
days respectively. Again, there were wide variations
in the numbers of tumour cells detected in
individual mice, even in those from mice with
tumours of similar age and diameter.
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mice bearing B16F1O melanomas or Lewis lung
carcinomas did not necessarily indicate that the
same mice also had tumorigenic cells in their lungs,
or vice versa. From Day 11 throughout tumour
growth -40% of B16F1O melanoma-bearing mice
had tumorigenic cancer cells in both blood and
lungs, but the incidence of melanoma-bearing mice
with melanoma cells in their blood but not lungs
was low (2%). Similarly, 60% of Lewis carcinoma-
bearers had tumorigenic cells in both the circulation
and lungs but <2% had cancer cells in their blood
only. Forty percent of melanoma-bearing mice and
15% of carcinoma-bearers had no detectable
circulating tumorigenic cells but did have
tumorigenic cells in their lungs. Similar proportions
of (20-25%) of melanoma- and Lewis carcinoma-
bearing animals had neither circulating nor tumori-
genic cells at the time of assay. An interesting
finding was that in the presence of circulating
cancer cells, 98% of animals had tumorigenic cells
in their lungs.
To examine the possibility that cancer cells
appearing in the blood or lungs during the first few
days of tumour growth were the result of
inadvertent introduction of tumour cells into the
circulation during the initial i.m. injections,
experiments were performed in which blood and
lungs of groups of 5 mice were bioassayed
immediately, 1 h and 4h after i.m. injections of
Lewis lung carcinoma cells. No cancer cells were
detected in blood or lungs of these mice.
Lung colonization potential
The results in Table V show that, following
injection of graded doses of cancer cells directly
into the circulation, between 103 and 104 melanoma
cells were needed to induce pulmonary nodules in
100% of mice and between 105 and 106 carcinoma
cells were needed to give the same incidence.
Experiments were also made to determine the
tumorigenicity of cancer cells shortly after their
arrest in the lungs. Groups of 5-10 mice were given
105 B16F1O melanoma cells via a tail vein. Five
minutes later, their lungs were removed for
bioassay and the results showed that the median
numbers of tumorigenic cells were only 7 x 103 and
8 x 103 in duplicate experiments. Two experiments
using Lewis lung carcinoma cells showed that the
numbers of tumorigenic cells were also rapidly
reduced to a similar extent within five minutes of
injection, from 106 originally injected to 6 x 104 and
7.5 x 104 in the two experiments.
Discussion
In common with earlier attempts to quantify release
of cancer cells from primary lesions by the use of
perfusion systems (Liotta et al., 1974; Butler &
Gullino, 1975), experiments involving direct
counting of circulating cancer cells (Glaves, 1983)
also give information about the influx of malignant
cells into the blood. However, the bioassay system
developed in the present studies provides a measure
of the biologically critical property of these
disseminated cancer cells, their potential
tumorigenicity.
Bioassays have been used previously to detect
otherwise covert cancer cells in tissues and body
fluids (Koike et al., 1964; Grazet, 1966; Donelli et
al., 1969; Wexler et al., 1971). However, in contrast
to the present study, these former assays were often
used to determine presence or absence of
tumorigenic cells with few attempts (Dobr6ssy &
Turi, 1976 Nakadate et al., 1979) to define the
limits of sensitivity of the assay or to obtain precise
quantification of tumour cell load throughout
tumour growth. The limiting dose bioassay method
used here indicates that there is an inherent
inefficiency of tumour development for both cell
types which is possibly a reflection of the various
host defense reactions mounted by the host against
Table V Pulmonary colonization potential of B16FIO melanoma and Lewis
lung carcinoma cells following i.v. injection
Pulmonary nodules?
No. cells B16FJO melanoma Lewis lung carcinoma
injected median range incidence median range incidence
106 b 32 19-33 4/4
i05 >500C 5/5 1 0-2 4/5
104 61 57-96 5/5 0 0-9 2/5
103 6 2-10 5/5 0 0-1 1/5
102 2 0-2 3/5 not done
a21 days after i.v. inoculations.
bmice died immediately after injection.
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malignant cells (Hanna, 1980; Goldfarb &
Herberman, 1982). However, by taking advantage
of the growth-promoting effects of lethally
irradiated cells (Revesz, 1955), the threshold dose is
reduced to 10-100 cells.
In many experimental studies of chemotherapy
regimens, lymphoid tumours such as the L1210 are
used because the numbers of cells surviving after
treatment can be accurately quantitated from
survival curves (Skipper et al., 1964, 1965) similar
to those used in the present studies. These earlier
studies relied upon the fact that these tumours will
grow reproducibly from doses of < 10 cells without
growth-promoting manipulations. The bioasscax
developed here, however, will permit examinations
of the effects of reduction therapy to be extended
to solid tumours since inclusion of irradiated cells
reduces the limits of quantitative detection to
similarly low levels.
In the present studies, systematic bioassays
showed that the entry of potentially tumorigenic
cells into the circulation can be an early event,
sometimes occurring within 4 days of tumour
inoculation. A previous report (Stackpole, 1981)
has indicated that cancer cells may be accidentally
disseminated during inocula-tion i-n:i.m. or-ther
extravascular sites. However, the present bioassays
detected no iatrogenically disseminated cells.
Although the numbers of tumorigenic cells in the
circulation increased progressively during tumour
growth, there were differences in the numbers of
circulating tumorigenic cells released from tumours
of the same age in duplicate experiments with the
same tumour. These differences were associated
with the growth rate of the intramuscular lesion
rather than solely tumour size and it is therefore
interesting to note that in vitro experiments have
demonstrated that the faster their growth rate, the
more easily cells may be detached from their
substrates (Weiss, 1964). There were also wide
fluctuations in the numbers of melanoma and
carcinoma cells in both the blood and lungs of
individual mice bearing tumours growing at the
same rate. Such variations were also apparent in a
study of circulating mouse lymphoma cells
(Schirrmacher & Waller, 1982). It is possible that
the rates at which cancer cells are released from a
primary tumour could be a characteristic property
of individual tumours. However, as previously
suggested (Glaves, 1983), an alternative explanation
is that these fluctuations reflect sporadic release of
showers of cancer cells into the circulation so that
samples taken over short periods of approximately
one minute will necessarily contain variable
numbers of cells depending upon the rate at which
cancer cells are being released at that time.
The increases in circulating tumorigenic cells
during primary tumour growth were paralleled by
progressive accumulations of tumorigenic cells in
the lungs. These cancer cells represent not only
those cells immediately shed from the primary
tumour, but also the progeny of earlier seedings.
However, the experiments with the B16F10
melanoma indicate that pulmonary seeding of
viable cancer cells resulted in as many as ten
thousand potentially tumorigenic cancer cells in the
lungs, yet no overt metastases are detectable at this
time. Similarly, in experiments in which Lewis
carcinoma cells were identified morphologically,
only occasional pulmonary metastases were
recorded until late in primary tumour growth, yet
orders of magnitude more carcinoma cells had been
seeded into the lungs by this time and most of these
were tumorigenic on bioassay. At least 102 B16FIO
cells were needed to generate pulmonary nodules in
a proportion of mice, even though this melanoma
variant was selected for high lung colonization
capacity (Fidler, 1973) and 103 Lewis carcinoma
cells were needed to generate at least one
pulmonary lesion. Nevertheless, the maximum lung
colonization potential of either tumour is not
realized during spontaneous metastasis. It has been
known for many years that relatively few cancer
cells-of any type prod-uce overt le-sions following
direct injection into the circulation and, in common
with the present studies, in those investigations in
which circulating cancer cells were shed
spontaneously from solid tumours, either metastases
did not occur (Butler & Gullino, 1975) or were
orders of magnitude less than the numbers of
cancer cells released from the primary lesion (Liotta
et al., 1974). This dose-response relationship has
recently been described as a contribution to "meta-
static inefficiency" (Weiss, 1982). The present study
shows that this inefficiency is not related to the
tumorigenic potential of cancer cells leaving the
primary tumour. This emphasizes the importance of
those active specific and non-specific defense
processes (Weiss & Glaves, 1976; Fidler et al., 1977;
Riccardi et al., 1979; Glaves, 1980) operating in the
lungs which contribute to the death of as many as
98% of these two types of tumour cells within 24h
of their initial arrest (Glaves, 1983; Fidler et al.,
1976). These previous reports describe the fate of
radiolabelled tumour cells retained in the lungs
after i.v. injections. Whilst the radiolabel used is
associated with intact and potentially viable cells,
the present experiments show that the vast majority
of tumour cells are rendered non-tumorigenic
within minutes of their arrest in the lungs.
However, even though most of the seeded cells may
die, the bioassays indicate that there is a
considerable excess of tumorigenic doses of cells in
the lungs at many times. These cells could represent
a reservoir for secondary or tertiary metastases
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host had not died as a consequence of the primary
tumour.
The numbers of circulating Lewis carcinoma cells
quantified by bioassay were within similar ranges to
those quantitated previously by direct counting
techniques (Glaves, 1983) which indicates firstly,
that the direct counting can be a reliable- method
for use where bioassays are impracticable.
Secondly, the majority of cancer cells released into
the venous circulation from intramuscular tumours
are viable and at least potentially capable of
generating secondary lesions. Independently and in
concert, these two observations can offer valuable
information about the quantitative and temporal
aspects of rate-limiting stages of the post-invasive
phases of metastasis. It will now be possible to
examine those host- or tumour-associated factors
which can potentially contribute to the release of
cancer cells from primary tumours. For example, in
vitro studies indicate that proteases may play an
important role in invasion of tissues or blood
vessels (Strauli et al., 1980), but this role can now
be quantitatively assessed directly, in vivo, during
spontaneous metastasis.
The therapy of metastatic disease is a particular
problem in cancer patients, and experimental
models in mice which could monitor the efficacy of
treatment would be a valuable asset to the
development of new treatment regimens, especially
where solid tumours and sub-clinical micro-
metastases or dormant cancer cells are involved.
The present studies emphasize the potential
magnitude of such sub-clinical populations of
cancer cells in distant organs and the bioassay
technique developed here offers a very sensitive and
quantitative method of monitoring the clinically
relevant property of these cells - their potential
tumorigenicity. Experiments are now in progress to
determine at which of the sequential steps of the
metastasis cascade anti-metastatic agents operate,
since the effects of therapy upon the primary
tumour, disseminating cells, subclinical populations
of cancer cells and overt metastases can now be
dissociated using the present experimental systems.
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